{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:25:53Z","timestamp":1789662353892,"version":"4.0.1"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360029"],"award-info":[{"award-number":["82360029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.molimm.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:17:56Z","timestamp":1770679076000},"page":"60-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dynamic immune yin-yang in chronic myeloproliferative neoplasms mechanisms, therapeutic implications, and future directions"],"prefix":"10.1016","volume":"191","author":[{"given":"Hanlu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuege","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/bloodadvances.2020003172","article-title":"Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature","volume":"5","author":"Alimam","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib2","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1038\/s41467-022-35645-z","article-title":"Author Correction: JAK2V617F mutation drives vascular resident macrophages toward a pathogenic phenotype and promotes dissecting aortic aneurysm","volume":"13","author":"Al-Rifai","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.molimm.2026.02.002_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.blre.2017.05.001","article-title":"Interleukin-1\u03b2 as emerging therapeutic target in hematological malignancies and potentially in their complications","volume":"31","author":"Arranz","year":"2017","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.molimm.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2014.97","article-title":"Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms","volume":"28","author":"Avanzini","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/bloodadvances.2021004379","article-title":"Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model","volume":"6","author":"Baldauf","year":"2022","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"6","key":"10.1016\/j.molimm.2026.02.002_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-a puzzle still to be solved","volume":"23","author":"Bhuria","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.molimm.2026.02.002_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164663","article-title":"A proliferation-inducing ligand and b-cell activating factor are upregulated in patients with essential thrombocythemia","volume":"11","author":"Bolkun","year":"2022","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.htct.2017.12.003","article-title":"Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation","volume":"40","author":"Cacemiro","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.molimm.2026.02.002_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772408","article-title":"Inflammatory cytokines shape an altered immune response during myeloid malignancies","volume":"12","author":"Camacho","year":"2021","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.002_bib12","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41375-024-02354-z","article-title":"Proteomic screening identifies PF4\/Cxcl4 as a critical driver of myelofibrosis","volume":"38","author":"Capitanio","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.molimm.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00277-018-3332-7","article-title":"Distinctive CD8(+) T cell and MHC class I signatures in polycythemia vera patients","volume":"97","author":"Cardoso","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.molimm.2026.02.002_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866610","article-title":"Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with t cell suppression","volume":"13","author":"Carnaz Sim\u00f5es","year":"2022","journal-title":"Front Immunol."},{"issue":"23","key":"10.1016\/j.molimm.2026.02.002_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16234113","article-title":"Shaping the future of myeloproliferative neoplasm therapy: immune-based strategies and targeted innovations","volume":"16","author":"Carturan","year":"2024","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.molimm.2026.02.002_bib16","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1016\/j.clml.2020.07.006","article-title":"Retrospective Analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis","volume":"20","author":"Castillo-Tokumori","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"17","key":"10.1016\/j.molimm.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2026.02.002_bib18","article-title":"Cytokine consistency between bone marrow and peripheral blood in patients with philadelphia-negative myeloproliferative neoplasms","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Cimen Bozkus","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molimm.2026.02.002_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/453020","article-title":"Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in myeloproliferative neoplasms","volume":"2015","author":"\u010coki\u0107","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"7","key":"10.1016\/j.molimm.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ajh.27322","article-title":"miR-146a(-\/-) mice model reveals that NF-\u03baB inhibition reverts inflammation-driven myelofibrosis-like phenotype","volume":"99","author":"Cuenca-Zamora","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.002_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092592","article-title":"Heat shock proteins and PD-1\/PD-L1 as potential therapeutic targets in myeloproliferative neoplasms","volume":"12","author":"De Almeida","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.molimm.2026.02.002_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365015","article-title":"Elevated levels of damage-associated molecular patterns HMGB1 and S100A8\/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis","volume":"15","author":"De Luca","year":"2024","journal-title":"Front Immunol."},{"issue":"19","key":"10.1016\/j.molimm.2026.02.002_bib24","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMc1503143","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Delhommeau","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"11","key":"10.1016\/j.molimm.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1111\/cas.15950","article-title":"Upregulated SPAG6 correlates with increased STAT1 and is associated with reduced sensitivity of interferon-\u03b1 response in BCR::ABL1 negative myeloproliferative neoplasms","volume":"114","author":"Ding","year":"2023","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.molimm.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-023-05284-5","article-title":"Contributions of bone marrow monocytes\/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation","volume":"102","author":"Fan","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.molimm.2026.02.002_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.768592","article-title":"Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms","volume":"13","author":"Fernandes de Oliveira Costa","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.molimm.2026.02.002_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ejh.12486","article-title":"Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis","volume":"95","author":"Geissler","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.molimm.2026.02.002_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/284706","article-title":"Impact of inflammation on myeloproliferative neoplasm symptom development","volume":"2015","author":"Geyer","year":"2015","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12967-023-04393-z","article-title":"Fibrosis and bone marrow: understanding causation and pathobiology","volume":"21","author":"Ghosh","year":"2023","journal-title":"J. Transl. Med."},{"issue":"18","key":"10.1016\/j.molimm.2026.02.002_bib35","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood.2019004095","article-title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN","volume":"136","author":"Gleitz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.molimm.2026.02.002_bib37","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"18","key":"10.1016\/j.molimm.2026.02.002_bib38","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.2020007943","article-title":"CXCL4's \"Gliful\" subversion of BM in MPN","volume":"136","author":"Gurbuxani","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.molimm.2026.02.002_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-Cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.molimm.2026.02.002_bib40","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","article-title":"PD-1 inhibition in advanced myeloproliferative neoplasms","volume":"5","author":"Hobbs","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/genes13030492","article-title":"CCL2 rs1024611Gene polymorphism in philadelphia-negative myeloproliferative neoplasms","volume":"13","author":"Hodeib","year":"2022","journal-title":"Genes"},{"issue":"16","key":"10.1016\/j.molimm.2026.02.002_bib42","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib44","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3324\/haematol.2024.285598","article-title":"Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis","volume":"110","author":"Jung","year":"2025","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.molimm.2026.02.002_bib45","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.2022018859","article-title":"Two to tango! IL-13 and TGF-\u03b2 drive myelofibrosis","volume":"140","author":"Jutzi","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molimm.2026.02.002_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109236","article-title":"Thromboinflammation in ischemic cerebrovascular patients with the JAK2V617F mutation","volume":"245","author":"Kristiansen","year":"2025","journal-title":"Thromb. Res."},{"issue":"26","key":"10.1016\/j.molimm.2026.02.002_bib48","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the european group for blood and marrow transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","article-title":"Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-\u03b1 in myeloproliferative neoplasm","volume":"3","author":"Lai","year":"2019","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3899\/jrheum.100214","article-title":"Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus","volume":"38","author":"Landolt-Marticorena","year":"2011","journal-title":"J. Rheuma"},{"issue":"5","key":"10.1016\/j.molimm.2026.02.002_bib51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.2022017097","article-title":"Therapeutic activity of GARP:TGF-\u03b21 blockade in murine primary myelofibrosis","volume":"141","author":"Lecomte","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cjp2.240","article-title":"PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients","volume":"8","author":"Lee","year":"2022","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.molimm.2026.02.002_bib53","article-title":"JAK2(V617F) mutation promoted IL-6 production and glycolysis via mediating PKM1 stabilization in macrophages","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","article-title":"Metabolism, metabolites, and macrophages in cancer","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"7203","key":"10.1016\/j.molimm.2026.02.002_bib55","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","article-title":"Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib","volume":"28","author":"Massa","year":"2014","journal-title":"Leukemia"},{"issue":"10302","key":"10.1016\/j.molimm.2026.02.002_bib57","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-021-00423-5","article-title":"Reduced CXCL4\/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera","volume":"11","author":"Meier-Abt","year":"2021","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib59","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.26461","article-title":"PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms","volume":"97","author":"Milosevic Feenstra","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00277-020-04304-y","article-title":"Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm","volume":"100","author":"Molitor","year":"2021","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.molimm.2026.02.002_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174400","article-title":"NK Cells in Myeloproliferative Neoplasms (MPN)","volume":"13","author":"Naismith","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041906","article-title":"Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies","volume":"22","author":"Nasillo","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.molimm.2026.02.002_bib66","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/eji.200635956","article-title":"BAFF costimulation of Toll-like receptor-activated B-1 cells","volume":"36","author":"Ng","year":"2006","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.21972","article-title":"Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.molimm.2026.02.002_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103862","article-title":"Anemia in myelofibrosis: Current and emerging treatment options","volume":"180","author":"Passamonti","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"16","key":"10.1016\/j.molimm.2026.02.002_bib69","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.molimm.2026.02.002_bib70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hoc.2020.12.007","article-title":"Immunotherapy and Immunomodulation in myeloproliferative neoplasms","volume":"35","author":"Pemmaraju","year":"2021","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib71","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","article-title":"CTLs heterogeneity and plasticity: implications for cancer immunotherapy","volume":"23","author":"Peng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molimm.2026.02.002_bib72","article-title":"The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12964-024-01877-3","article-title":"Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology","volume":"22","author":"Peroni","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"429","key":"10.1016\/j.molimm.2026.02.002_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med"},{"issue":"6","key":"10.1016\/j.molimm.2026.02.002_bib76","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib77","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","article-title":"Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm","volume":"13","author":"Rai","year":"2022","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.molimm.2026.02.002_bib78","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2020005563","article-title":"JAK2-V617F and interferon-\u03b1 induce megakaryocyte-biased stem cells characterized by decreased long-term functionality","volume":"137","author":"Rao","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12687","article-title":"Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera","volume":"97","author":"Riley","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.12420","article-title":"Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1","volume":"94","author":"Riley","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib81","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hon.2769","article-title":"Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib","volume":"38","author":"Rumi","year":"2020","journal-title":"Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.molimm.2026.02.002_bib82","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1002\/ajh.25489","article-title":"Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms","volume":"94","author":"Rumi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.molimm.2026.02.002_bib83","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T Cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev. Immunol."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.molimm.2026.02.002_bib85","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Sch\u00f6nberg","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/ehm.12.69","article-title":"Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"6","author":"Silver","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib87","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1620\/tjem.2024.J029","article-title":"Expression of CD4(+)T Cells in myeloproliferative diseases and the effect of ruxolitinib treatment on prognosis","volume":"263","author":"Song","year":"2024","journal-title":"Tohoku J. Exp. Med."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib88","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/ejh.13292","article-title":"B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-\u03b12, or combination treatment","volume":"103","author":"S\u00f8rensen","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.molimm.2026.02.002_bib90","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/bjh.17850","article-title":"The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy","volume":"196","author":"Strickland","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.molimm.2026.02.002_bib91","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3904\/kjim.2018.033","article-title":"Recent advances in the diagnosis and management of primary myelofibrosis","volume":"33","author":"Takenaka","year":"2018","journal-title":"Korean J. Intern Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.molimm.2026.02.002_bib93","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/ajh.27428","article-title":"Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts","volume":"99","author":"Tavernari","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.molimm.2026.02.002_bib94","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.molimm.2026.02.002_bib95","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.molimm.2026.02.002_bib96","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3324\/haematol.2020.249441","article-title":"Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis","volume":"106","author":"Veletic","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib97","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10875-025-01871-5","article-title":"Bone Marrow CD8\u2009+\u2009abundance inversely correlates with progressive marrow fibrosis and myelodysplastic evolution in GATA2 Deficiency: case Report","volume":"45","author":"Vendemini","year":"2025","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.molimm.2026.02.002_bib98","first-page":"2060","article-title":"CXCL8 and its cognate receptors CXCR1\/CXCR2 in primary myelofibrosis","volume":"109","author":"Vermeersch","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.molimm.2026.02.002_bib99","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.molimm.2026.02.002_bib100","article-title":"Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2R\u03b1","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.molimm.2026.02.002_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105837","article-title":"PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in Ph(-) myeloproliferative neoplasm: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib102","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","article-title":"Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies","volume":"11","author":"Wang","year":"2023","journal-title":"Biomark. Res."},{"issue":"15","key":"10.1016\/j.molimm.2026.02.002_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512502","article-title":"Role of next generation immune checkpoint inhibitor (ICI) therapy in philadelphia negative classic myeloproliferative neoplasm (MPN): review of the literature","volume":"24","author":"Yadav","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molimm.2026.02.002_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaut.2017.12.011","article-title":"CD8(+) T cells and IFN-\u03b3 induce autoimmune myelofibrosis in mice","volume":"89","author":"Yao","year":"2018","journal-title":"J. Autoimmun."},{"issue":"11","key":"10.1016\/j.molimm.2026.02.002_bib105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154092","article-title":"TGF-\u03b2 signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche","volume":"132","author":"Yao","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.molimm.2026.02.002_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925266","article-title":"The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.02.002_bib107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589026000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:44:55Z","timestamp":1776181495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589026000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":107,"alternative-id":["S0161589026000283"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2026.02.002","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic immune yin-yang in chronic myeloproliferative neoplasms mechanisms, therapeutic implications, and future directions","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}